Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A2/4-1BBL melanoma vaccine in high risk or low residual disease melanoma
NCT01898039Phase 2Recruiting
- Sponsor
- Hadassah Medical Organization
- Start
- May 2013
- Primary completion
- Apr 2027
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of A2/4-1BBL in Malignant Melanoma (MM), sponsored by Hadassah Medical Organization. Primary endpoints: Adverse Events at Month 6 and Anti-tumor immune response at Month 6. Started May 2013; status: recruiting.
02
Drugs
A2/4-1BBL
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT01898039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01898039.